| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/18/2002 | WO2002055099A2 Modulation of pericyte proliferation using bpi protein products or bpi inhibitors |
| 07/18/2002 | WO2002055087A1 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain |
| 07/18/2002 | WO2002055077A1 Use of imidazolyl cyclic acetal derivatives in the manufacture of a medicament for the treatment of diseases mediated by the alk5 receptors |
| 07/18/2002 | WO2002055072A1 Regulation of lipids and/or bone density and compositions therefor |
| 07/18/2002 | WO2002055071A1 Compositions and methods for regulating lipoproteins and hypercholesterolmia with limonoids flavonoids and tocotrienols |
| 07/18/2002 | WO2002055063A2 Fumaric acid amides |
| 07/18/2002 | WO2002055010A2 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 07/18/2002 | WO2002055009A1 Spaced drug delivery system |
| 07/18/2002 | WO2002054851A2 Inhibition of pathological angiogenesis in vivo |
| 07/18/2002 | WO2002041834A3 Atorvastatin hemi-calcium form vii |
| 07/18/2002 | WO2002039978A8 Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition |
| 07/18/2002 | WO2002034202A3 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 07/18/2002 | WO2002029088A3 Highly expressible genes |
| 07/18/2002 | WO2002022558A3 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 07/18/2002 | WO2002016549A3 METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE |
| 07/18/2002 | WO2002013758A3 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 07/18/2002 | WO2002011704A3 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 07/18/2002 | WO2002006316A3 Alpha-msh related compounds and methods of use |
| 07/18/2002 | WO2002006242A3 5-substituted 2-aryl-4-pyrimidinones |
| 07/18/2002 | WO2002006218A3 STABILIZED 1α-HYDROXY VITAMIN D |
| 07/18/2002 | WO2002002633A3 Transporters and ion channels |
| 07/18/2002 | WO2001094391A3 Intracellular signaling proteins |
| 07/18/2002 | WO2001090103A3 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators |
| 07/18/2002 | WO2001085790A3 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 07/18/2002 | WO2001083749A3 Gene and sequence variation associated with sensing carbohydrate compounds and other sweeteners |
| 07/18/2002 | WO2001083525A3 Modified peptides, comprising an fc domain, as therapeutic agents |
| 07/18/2002 | WO2001081590A3 Protein phosphatases |
| 07/18/2002 | WO2001081408A3 G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same |
| 07/18/2002 | WO2001080847A3 Combination of carboxyalkylethers with antihypertensives and pharmaceutical use |
| 07/18/2002 | WO2001079282A3 Molecules associated with human reproduction |
| 07/18/2002 | WO2001078534A3 Beta-glucan compositions for reducing hypercholesterolemia and controlling of postprandial blood glucose and insulin levels |
| 07/18/2002 | WO2001077072A3 Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality |
| 07/18/2002 | WO2001072728A3 Novel piperazine derivatives |
| 07/18/2002 | WO2001066747A3 Proteins named fctrx and nucleic acids encoding same |
| 07/18/2002 | WO2001056547A3 Preparation of aqueous clear solution dosage forms with bile acids |
| 07/18/2002 | WO2001049295A9 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 07/18/2002 | WO2001045679A3 Use of chemotherapeutic agents for topical treatment |
| 07/18/2002 | WO2001039766A3 Screening invertebrate pheromones for therapeutic activity |
| 07/18/2002 | WO2001005834A9 Human tumor necrosis factor receptors tr13 and tr14 |
| 07/18/2002 | WO2000078972A9 Regulation with binding cassette transporter protein abc1 |
| 07/18/2002 | US20020095135 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| 07/18/2002 | US20020095024 B7-related nucleic acids and polypeptides useful for immunomodulation |
| 07/18/2002 | US20020095002 Process for removing bile salts from a patient and alkylated compositions thereor |
| 07/18/2002 | US20020094996 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases |
| 07/18/2002 | US20020094992 Administering growth hormone secretagogue which is 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridin-5-yl)1-(R)-benzyloxymet hyl-2-oxo-ethyl)-isobutyramide, salt or prodrug |
| 07/18/2002 | US20020094980 Preparing 1,1-dioxo-2-phenyl-3-carboxy-4-phenyl-1,2-benzo(e)-thiazines by a five-step process starting with a (2-(methyl-oxycarbonyl-)phenyl-sulfonamido-)benzene; alkylation; cyclization; hydroxylation; esterification and coupling |
| 07/18/2002 | US20020094977 Benzo(3,4)pyrido(3,2-a)cycloctenes and benzo(3,4)pyrido-(3,2-a)oxocins, -thiocins or azocines; anticholesterol, antilipemic agents; lowering LDL cholesterol; increasing HDl cholesterol; hypertriglyceridemia and atherosclerosis |
| 07/18/2002 | US20020094971 Hyperglucemic, antidiabetic agents comprising a granulated starch having a reduced surface available for enzymatic degradation to delay production of reducing sugars; oral time-release agents; surgical patients; athletes |
| 07/18/2002 | US20020094969 Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
| 07/18/2002 | US20020094960 Specifically unipolar depression, treatment-refractory depression, resistant depression, anxious depression and dysthymia; 2-sulfamatomethyltetrahydropyrans and sulfamato-methylcyclohexanes, e.g. topiramate |
| 07/18/2002 | US20020094955 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 07/18/2002 | US20020094350 Compositions containing an active fraction isolated from scutellariae barbatae and methods of use |
| 07/18/2002 | US20020094318 Dispersible dry powder of a therapeutic agent such as insulin with an aerogel particle which is soluble in human pulmonary surfactant, such as sugars and carbohydrates |
| 07/18/2002 | DE10102050A1 Food, nutritional supplement, feed or medicament preparations containing conjugated cis/trans-octatrienoic acid, useful e.g. for reducing food intake, improving food utilization or treating cancer or diabetes |
| 07/18/2002 | DE10064312A1 Cholinpyruvat, Verfahren zu dessen Herstellung, Cholinpyruvat enthaltende Formulierung sowie deren Verwendung Choline pyruvate, containing process for the production thereof, choline pyruvate formulation and the use thereof |
| 07/18/2002 | CA2776023A1 Fumaric acid amides |
| 07/18/2002 | CA2725833A1 Spaced drug delivery system |
| 07/18/2002 | CA2436876A1 Transcriptional mediators of blood vessel development and endothelial differentiation |
| 07/18/2002 | CA2434672A1 Sfrp and peptide motifs that interact with sfrp and methods of their use |
| 07/18/2002 | CA2434567A1 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 07/18/2002 | CA2434543A1 Inhibition of pathological angiogenesis in vivo |
| 07/18/2002 | CA2434330A1 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
| 07/18/2002 | CA2434274A1 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them |
| 07/18/2002 | CA2433742A1 Proteins and nucleic acids encoding same |
| 07/18/2002 | CA2433653A1 Regulation of lipids and/or bone density and compositions therefor |
| 07/18/2002 | CA2433449A1 Metabolic gene polynucleotides and polypeptides and uses thereof |
| 07/18/2002 | CA2433066A1 Novel multi-ring organic compounds for regulating gut motility and food intake |
| 07/18/2002 | CA2432114A1 4-(hetero)aryl substituted indolinones |
| 07/18/2002 | CA2430588A1 Modulation of pericyte proliferation using bpi protein products or bpi inhibitors |
| 07/18/2002 | CA2428497A1 Targeted modification of intracellular compounds |
| 07/17/2002 | EP1223221A2 Recombinant vector for use in gene therapy for insulindependent diabetes mellitus and therapeutic composition thereof |
| 07/17/2002 | EP1222927A2 Pharmaceutical compositions having appetite suppressant activity |
| 07/17/2002 | EP1222920A2 Mitochondria protecting agents for treating mitochondria associated diseases |
| 07/17/2002 | EP1222463A2 Allosteric sites on muscarinic receptors |
| 07/17/2002 | EP1222313A2 Genes associated with obesity and methods for using the same |
| 07/17/2002 | EP1222277A2 Endozepine-like polypeptides and polynucleotides encoding same |
| 07/17/2002 | EP1222273A2 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 07/17/2002 | EP1222270A2 Proteins and polynucleotides encoded thereby |
| 07/17/2002 | EP1222251A1 Ex vivo generation of functional osteoclasts from bone marrow in a three-dimensional bioreactor |
| 07/17/2002 | EP1222209A2 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 07/17/2002 | EP1222208A1 Polypeptide derivatives of parathyroid hormone (pth) |
| 07/17/2002 | EP1222203A1 Method of altering polypeptide aggregation |
| 07/17/2002 | EP1222202A2 Ab5 toxin b subunit mutants with altered chemical conjug ation characteristics |
| 07/17/2002 | EP1222193A2 Imidazole derivatives as phosphodiesterase vii inhibitors |
| 07/17/2002 | EP1222191A2 Benzodiazepin derivatives, the production and use thereof |
| 07/17/2002 | EP1222188A1 Novel imidazopyridine carbonitrile compounds |
| 07/17/2002 | EP1222187A2 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 07/17/2002 | EP1222183A1 Benzopyran derivatives |
| 07/17/2002 | EP1222171A1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 07/17/2002 | EP1222170A1 Novel nicotinonitrile compounds |
| 07/17/2002 | EP1222169A1 Novel trisubstituted pyridine compounds |
| 07/17/2002 | EP1221973A1 CD40 antagonist for treating psoriasis |
| 07/17/2002 | EP1221941A1 Powder pharmaceutical formulations |
| 07/17/2002 | EP1221939A1 Ortho ester lipids |
| 07/17/2002 | EP1221868A1 Dietary supplement |
| 07/17/2002 | EP1221865A2 Food supplement for increasing lean mass and strength |
| 07/17/2002 | EP0969860B1 Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer |
| 07/17/2002 | EP0851865B1 12H-Dibenzo[d,g][1,3]dioxocine derivatives |
| 07/17/2002 | CN1359383A Benzopyrans and benzoxepines, pharmaceutical compositions comprising them and preparation process |
| 07/17/2002 | CN1359378A 2-oxy-benzoxazine derivatives for the treatment of obesity |